徐放性医薬品の世界市場レポート 2025年

徐放性医薬品市場規模は、今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）12.6%で1,130億5,000万米ドルに成長します。予測期間の成長は、個別化医療へのアプローチ、患者中心の医薬品開発、生活習慣病の罹患率の上昇、薬剤の再利用、徐放性療法への世界のアクセスに起因すると考えられます。予測期間の主な動向には、医薬品の革新、ドラッグデリバリーシステムの進歩、ナノテクノロジーの進歩、薬剤製剤における3dプリンティング、人工知能の利用、環境の持続可能性などが含まれます。

予想される慢性疾患の発生率の上昇は、徐放性医薬品市場の成長を促進する態勢を整えています。慢性疾患は、1年以上持続し、継続的な医療を必要とすることが特徴で、日常生活に影響を及ぼします。心臓病、がん、肥満、糖尿病などがその例です。徐放性ドラッグデリバリーシステムは、長期間にわたって体内の薬物濃度を一定に保つよう特別に設計されており、安定した治療効果を確保し、即時放出薬で起こりうる薬物濃度の変動を最小限に抑えます。2023年1月の全米生物工学情報センター（NCBI）の予測によると、少なくとも1つの慢性疾患を持つ50歳以上の人口は、2050年までに99.5％急増し、1億4,266万人に達すると予想されています。このように、慢性疾患の罹患率の増加は、徐放性医薬品市場の成長の大きな原動力となっています。

製薬業界における需要の増加は、徐放性医薬品市場の拡大を促進すると予想されます。医薬品や薬剤の発見、開発、生産、マーケティングに集中する製薬業界では、徐放性医薬品の採用が増加しています。これらの医薬品は、患者のコンプライアンス向上、治療成績の向上、投与頻度の低減、血流中の薬物濃度の安定、副作用の最小化、症状変動の低減、全体的な医薬品体験の向上に貢献しています。2023年6月、欧州製薬団体連合会（EFPIA）は、2022年の欧州の医薬品総生産額が3,842億米ドル（3,400億ユーロ）に達し、前年から4.95％増加したと報告しました。製薬業界における需要の高まりが、徐放性医薬品市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界徐放性医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の徐放性医薬品市場：成長率分析
• 世界の徐放性医薬品市場の実績：規模と成長, 2019-2024
• 世界の徐放性医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界徐放性医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の徐放性医薬品市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 徐放性薬剤
• 徐放性薬剤
• 世界の徐放性医薬品市場モード別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 店頭
• 処方箋
• 世界の徐放性医薬品市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• 通信販売薬局
• ドラッグストア
• 世界の徐放性医薬品市場徐放性薬剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• マトリックスシステム
• コーティングシステム
• 世界の徐放性医薬品市場、放出制御薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 浸透圧システム
• マイクロカプセル化システム
• ターゲットデリバリーシステム

第7章 地域別・国別分析

• 世界の徐放性医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の徐放性医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 徐放性医薬品市場：競合情勢
• 徐放性医薬品市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Teva Pharmaceuticals Inc.
• Eastman Chemical Company
• Catalent Pharma Solutions Inc.
• Sun Pharmaceutical Industries Limited
• Purdue Pharma LP
• Amneal Pharmaceuticals Inc.
• Endo Pharmaceuticals Inc.
• Mallinckrodt LLC
• Allergan plc
• Hisamitsu Pharmaceutical Co. Inc.
• Janssen Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 徐放性医薬品市場2029：新たな機会を提供する国
• 徐放性医薬品市場2029：新たな機会を提供するセグメント
• 徐放性医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Extended-release drugs are a specific dosage form designed to release medication gradually over an extended period, following a predetermined rate, duration, and location in a controlled manner. This enables patients to take the medication less frequently compared to immediate-release forms, often requiring only 1 to 2 doses per day instead of 3 to 4.

The main types of extended-release drugs include sustained-release drugs and controlled-release drugs. Sustained-release drugs are medications intended to slowly release in the body over time, primarily to maintain therapeutic levels. These drugs are available in both over-the-counter and prescription forms and are distributed through various channels, including hospital pharmacies, retail pharmacies, mail-order pharmacies, and drug store channels.

The extended-release drugs research report is one of a series of new reports from The Business Research Company that provides extended-release drugs market statistics, including the extended-release drugs industry's global market size, regional shares, competitors with extended-release drugs market share, detailed extended-release drugs market segments, market trends and opportunities, and any further data you may need to thrive in the extended-release drugs industry. This extended-release drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The extended-release drugs market size has grown rapidly in recent years. It will grow from $63.11 billion in 2024 to $70.28 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to patient compliance improvement, chronic disease prevalence, improved efficacy, patent protection strategy, biodegradable implants

The extended-release drugs market size is expected to see rapid growth in the next few years. It will grow to $113.05 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to personalized medicine approaches, patient-centric drug development, rising incidence of lifestyle diseases, drug repurposing, global access to extended-release therapies. Major trends in the forecast period include pharmaceutical innovation, advancements in drug delivery systems, advancements in nanotechnology, 3d printing in drug formulations, use of artificial intelligence, environmental sustainability.

The anticipated rise in the incidence of chronic conditions is poised to drive the growth of the extended-release drug market. Chronic conditions are characterized by lasting a year or longer and requiring ongoing medical care, impacting everyday activities. Heart disease, cancer, obesity, and diabetes are examples of such conditions. Extended-release drug delivery systems are specifically designed to maintain a consistent medication level in the body over an extended period, ensuring a steady therapeutic effect and minimizing fluctuations in drug levels that can occur with immediate-release medications. As per projections from the National Center for Biotechnology Information (NCBI) in January 2023, the number of individuals aged 50 years and older with at least one chronic illness is expected to surge by 99.5% by the year 2050, reaching 142.66 million. Thus, the increasing incidence of chronic conditions is a significant driver of the extended-release drug market's growth.

The growing demand within the pharmaceutical industry is anticipated to fuel the expansion of the extended-release drugs market. The pharmaceutical industry, which concentrates on the discovery, development, production, and marketing of drugs and medications, is witnessing increased adoption of extended-release drugs. These drugs contribute to improved patient compliance, enhanced therapeutic outcomes, reduced administration frequency, steady drug levels in the bloodstream, minimized side effects, reduced symptom fluctuations, and an overall enhanced pharmaceutical experience. In June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that the total pharmaceutical production in Europe reached $384,200 million (€340,000 million) in 2022, marking a 4.95% increase from the previous year. The rising demand in the pharmaceutical industry is thereby propelling the extended-release drugs market.

A key trend gaining momentum in the extended-release drug market is product innovation. Major companies operating in this market are focusing on developing innovative products to maintain their market position. For example, in July 2022, Zydus Pharmaceuticals (USA) Inc., a US-based generic pharmaceutical manufacturer, introduced Topiramate extended-release capsules for epilepsy. The US Food and Drug Administration (USFDA) had previously approved the company to commercialize these capsules, making it the first business in the country to receive final approval for and launch Topiramate extended-release capsules. These capsules are approved for individuals with partial onset or primary generalized tonic-clonic seizures. Product innovation remains a crucial strategy for companies in the extended-release drug market.

Major companies in the extended-release drugs market are also innovating by developing new products such as next-generation extended-release tablets to enhance their product offerings and gain a competitive edge. Extended-release tablets are a specific pharmaceutical formulation designed to release active ingredients gradually over an extended period. In February 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Austedo XR (deutetrabenazine). This extended-release tablet is recommended for treating adults with chorea and tardive dyskinesia related to Huntington's disease. With dosages available in 6, 12, and 24 mg, Austedo XR provides a once-daily administration option, offering an efficient treatment alternative for patients with certain movement disorders. Such developments in next-generation extended-release tablets signify significant progress in managing movement disorders.

In March 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, completed the acquisition of Arena Pharmaceuticals for approximately $6.7 billion. This strategic acquisition grants Pfizer access to a portfolio of promising development-stage pharmaceutical prospects from Arena Pharmaceuticals, particularly in cardiology, dermatology, and gastroenterology. Arena Pharmaceuticals, a US-based biopharmaceutical company, specializes in small-molecule extended-release medications under development for potential clinical use in various therapeutic fields.

Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.

North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the extended-release drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The extended-release drug market consists of sales of extended-release tablets, extended-release capsules, and implants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Extended-Release Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on extended-release drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for extended-release drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The extended-release drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Sustained Release Drug; Controlled Release Drug
• 2) By Mode: Over-The-Counter; Prescription
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Mail Order Pharmacies; Drug Stores
• Subsegments:
• 1) By Sustained Release Drug: Matrix Systems; Coating Systems
• 2) By Controlled Release Drug: Osmotic Systems; Microencapsulation Systems; Targeted Delivery Systems
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Novartis AG; Sanofi SA; GlaxoSmithKline PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Extended-Release Drugs Market Characteristics

3. Extended-Release Drugs Market Trends And Strategies

4. Extended-Release Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Extended-Release Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Extended-Release Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Extended-Release Drugs Market Growth Rate Analysis
• 5.4. Global Extended-Release Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Extended-Release Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Extended-Release Drugs Total Addressable Market (TAM)

6. Extended-Release Drugs Market Segmentation

• 6.1. Global Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sustained Release Drug
• Controlled Release Drug
• 6.2. Global Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Over-The-Counter
• Prescription
• 6.3. Global Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies
• Drug Stores
• 6.4. Global Extended-Release Drugs Market, Sub-Segmentation Of Sustained Release Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Matrix Systems
• Coating Systems
• 6.5. Global Extended-Release Drugs Market, Sub-Segmentation Of Controlled Release Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Osmotic Systems
• Microencapsulation Systems
• Targeted Delivery Systems

7. Extended-Release Drugs Market Regional And Country Analysis

• 7.1. Global Extended-Release Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Extended-Release Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Extended-Release Drugs Market

• 8.1. Asia-Pacific Extended-Release Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Extended-Release Drugs Market

• 9.1. China Extended-Release Drugs Market Overview
• 9.2. China Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Extended-Release Drugs Market

• 10.1. India Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Extended-Release Drugs Market

• 11.1. Japan Extended-Release Drugs Market Overview
• 11.2. Japan Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Extended-Release Drugs Market

• 12.1. Australia Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Extended-Release Drugs Market

• 13.1. Indonesia Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Extended-Release Drugs Market

• 14.1. South Korea Extended-Release Drugs Market Overview
• 14.2. South Korea Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Extended-Release Drugs Market

• 15.1. Western Europe Extended-Release Drugs Market Overview
• 15.2. Western Europe Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Extended-Release Drugs Market

• 16.1. UK Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Extended-Release Drugs Market

• 17.1. Germany Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Extended-Release Drugs Market

• 18.1. France Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Extended-Release Drugs Market

• 19.1. Italy Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Extended-Release Drugs Market

• 20.1. Spain Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Extended-Release Drugs Market

• 21.1. Eastern Europe Extended-Release Drugs Market Overview
• 21.2. Eastern Europe Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Extended-Release Drugs Market

• 22.1. Russia Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Extended-Release Drugs Market

• 23.1. North America Extended-Release Drugs Market Overview
• 23.2. North America Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Extended-Release Drugs Market

• 24.1. USA Extended-Release Drugs Market Overview
• 24.2. USA Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Extended-Release Drugs Market

• 25.1. Canada Extended-Release Drugs Market Overview
• 25.2. Canada Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Extended-Release Drugs Market

• 26.1. South America Extended-Release Drugs Market Overview
• 26.2. South America Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Extended-Release Drugs Market

• 27.1. Brazil Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Extended-Release Drugs Market

• 28.1. Middle East Extended-Release Drugs Market Overview
• 28.2. Middle East Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Extended-Release Drugs Market

• 29.1. Africa Extended-Release Drugs Market Overview
• 29.2. Africa Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Extended-Release Drugs Market Competitive Landscape And Company Profiles

• 30.1. Extended-Release Drugs Market Competitive Landscape
• 30.2. Extended-Release Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis

31. Extended-Release Drugs Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Gilead Sciences Inc.
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Viatris Inc.
• 31.5. Teva Pharmaceuticals Inc.
• 31.6. Eastman Chemical Company
• 31.7. Catalent Pharma Solutions Inc.
• 31.8. Sun Pharmaceutical Industries Limited
• 31.9. Purdue Pharma LP
• 31.10. Amneal Pharmaceuticals Inc.
• 31.11. Endo Pharmaceuticals Inc.
• 31.12. Mallinckrodt LLC
• 31.13. Allergan plc
• 31.14. Hisamitsu Pharmaceutical Co. Inc.
• 31.15. Janssen Pharmaceuticals Inc.

32. Global Extended-Release Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Extended-Release Drugs Market

34. Recent Developments In The Extended-Release Drugs Market

35. Extended-Release Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Extended-Release Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Extended-Release Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Extended-Release Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer